Notice of annual general meeting in CombiGene
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail.
The shareholders of CombiGene AB (publ) are hereby summoned to attend the Annual General Meeting (“AGM”) on 25 May 2021 at 10.00 CEST in The Old Boardroom (fifth floor) at Medicon Village, Nytänkargatan 4, Lund. Registration starts at 09.30 CEST and will stop when the meeting starts.
CombiGene cherishes the health of the shareholders and strives to contribute in the best possible way in limiting the spread of the coronavirus. As a part of this, CombiGene will comply with current restrictions and government recommendations. For this reason, shareholders are urged to take advantage of the opportunity to vote via proxies. Furthermore, CombiGene has resolved that the registration of voting rights shall take place outdoors, that the premises shall be cleaned an extra time before the AGM and that hand sanitizer and face masks shall be provided.
Right to participate
Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as per 17 May 2021, and who, no later than 19 May 2021, give notice to the company of their intent to participate at the AGM have a right to participate at the AGM. Notice to participate shall be given in writing to CombiGene AB (publ), c/o Fredersen Advokatbyrå AB, Turning Torso, 211 15 Malmö or by e-mail to firstname.lastname@example.org. The notice shall contain the shareholder’s name, personal identity number or registration number and telephone number and, where applicable, the number of advisors (maximum two). Prior to the AGM, the shareholder will receive a confirmation. If no confirmation is received, notice has not been duly given.
In order to attend the AGM, the shareholders whose shares are registered under the name of a nominee, must temporarily register their shares in their own name in the share register kept by Euroclear SwedenAB. Such registration must be executed no later than 17 May 2021 and should be requested with the nominee well in advance.
Suggestion – New Articles of association decision point 16b (only in swedish) >>
Suggestion – New Articles of association decision point 17b (only in swedish) >>
Suggestion – New Articles of association decision point 18 (only in swedish) >>
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.